The incidence of urolithiasis (kidney/renal stones) depends on geographic, climatic, ethnic, dietary, and genetic factors. Assistant Professor Chua Wei Jin, Senior Consultant, Department of Urology at the National University Hospital in Singapore discusses with Audrey Abella why urolithiasis is an important healthcare problem that requires attention.
Chronic kidney disease (CKD) has a global prevalence of 7–12 percent, with a mortality risk that has increased over the past 25 years – ranking 25th in 1990 to 17th in 2015. While there is no sufficient data reflecting the incidence of CKD in South East Asia (SEA), in Singapore, 2.3 percent of adults aged 18–69 years have been found to have renal impairment (estimated glomerular filtration rate [eGFR] of <60 mL/min/1.73m2).
According to the Singapore National Registry of Diseases Office (NRDO), prostate cancer is the third most common cancer and the sixth most common cause of cancer-related deaths affecting men in Singapore. Dr Daniel Tan, radiation oncologist and medical director of Asian American Radiation Oncology at Gleneagles Hospital, Singapore, speaks to Roshini Claire Anthony on the importance of early detection of prostate cancer and the challenges associated with diagnosing and treating this condition.
The prevalence of benign prostate hypertrophy (BPH) increases with age and is more common in men aged 50 years and above. Dr Ronny Tan, consultant urologist and director of andrology at Tan Tock Seng Hospital, Singapore, speaks on how GPs can best manage this condition.
Use of complementary and alternative medicine (CAM) is common among patients with prostate cancer and has seen an increase among those who are newly diagnosed with the disease, a study has shown. Multivitamins and omega-3 fatty acids are the most commonly used CAMs from 1996 to 2016, while vitamin D use has increased dramatically from 2006 to 2010.
Cabozantinib was no better than the combination of mitoxantrone and prednisone for pain relief in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, according to the findings of the COMET-2* trial.